Nchi: Israeli
Lugha: Kiingereza
Chanzo: Ministry of Health
FUROSEMIDE
NEOPHARM (ISRAEL) 1996 LTD
C03CA01
SOLUTION FOR INJECTION
FUROSEMIDE 20 MG / 2 ML
I.M, I.V
Required
LABESFAL - LABORATORIOS ALMIRO S.A, FRESENIUS KABI GROUP, PORTUGAL
FUROSEMIDE
Furosemide is a potent diuretic indicated for use when a prompt and effective diuresis is required.Furosemide Injection 20mg/2ml is appropriate for use in emergencies or where oral therapy is not feasible.The indications include cardiac, pulmonary, hepatic and renal oedema.
2022-02-28
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT FUROSEMIDE - FRESENIUS 20 MG/ 2 ML 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml solution contains Furosemide 10 mg. Each 2 ml ampoule contains Furosemide 20 mg. For a full list of the excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. clear, colourless to almost colourless solution. 4. CLINICAL INFORMATION 4.1. Therapeutic indications Furosemide is a potent diuretic indicated for use when a prompt and effective diuresis is required. Furosemide injection 20mg/2ml is appropriate for use in emergencies or when oral therapy is not feasible. The indications include cardiac, pulmonary, hepatic and renal oedema. 4.2. Posology and method of administration Route of administration: intramuscular or intravenous use. _ _ _Adults _ Intravenous furosemide must be injected or infused slowly; a rate of 4 mg per minute must not be exceeded. In patients with severe impairment of renal function (serum creatinine >5 mg/dl), it is recommended that an infusion rate of 2.5 mg per minute is not exceeded. Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration is feasible. It must be noted that intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema. To achieve optimum efficacy and suppress counterregulation, a continuous furosemide infusion is generally to be preferred to repeated bolus injections. Where continuous furosemide infusion is not feasible for follow-up treatment after one or several acute bolus doses, a follow-up regimen with low doses given at short intervals (approximately four hours) is to be preferred to a regimen with higher bolus doses at longer intervals. Doses of 20 to 50 mg intramuscularly or intravenously may be given initially. If larger doses are required, they should be given by 20 mg increments and not given more often than every two hours. If doses greater than 50 mg are required, it is recommended that Soma hati kamili